Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-600-2 | CAS number: 7647-17-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
According to the results of an acute oral toxicity study with cesium chloride and acute dermal toxicity studies with two structural analogous read-across substances cesium chloride is not classified according to Regulation (EC) No 1272/2008 (CLP/GHS).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- no data
- Reliability:
- 4 (not assignable)
- Qualifier:
- according to guideline
- Guideline:
- other: no data
- GLP compliance:
- not specified
- Test type:
- other: no data
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Route of administration:
- other: oral
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 2 600 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- Toxicity Category V
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 of cesium chloride in rats was determined to be 2600 mg/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 600 mg/kg bw
- Quality of whole database:
- WoE approach with different studies in mice and rats which reveal values within the same range
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2012-01-24 to 2012-02-22
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: CLP, guideline and GLP compliant study. An experimental study was performed with a structural analogous read-across substance.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- , adopted 1987
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- , adopted 1992
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Version / remarks:
- ,adopted 1998
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Toxi-Coop Zrt. 1103 Budapest, Cserkesz u. 90.
- Age at study initiation: Young adult rats, 11 /12 weeks old
- Weight at study initiation: Male 272-300 g, Female 217-242 g
- Fasting period before study: food but not water was withheld overnight
- Housing: 5 animals/sex/cage
- Diet: ad libitum (ssniff® SM R/M-Z+H complete diet )
- Water: ad libitum
- Acclimation period: 5 days for the pre-study, 19 days for the main study
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30 - 70 %
- Air changes (per hr): 8-12 air exchanges/hour by central air-condition system.
- Photoperiod: Artificial light, from 6 a.m. to 6 p.m. - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: approximately 10 % of the total body surface
- Type of wrap if used: sterile gauze pad below a semi-occlusive plastic wrap
REMOVAL OF TEST SUBSTANCE
- Washing: water pre-warmed to body temperature
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount applied: Main-tests: 2000 mg/kg bw; pre-test: Pre-test: 5 mg/kg bw, 50 mg/kg bw, 300 mg/kg bw, 2000 mg/kg bw
- Constant volume or concentration used: yes - Duration of exposure:
- single administration for 24 hours
- Doses:
- Main-test
2000 mg/kg bw - No. of animals per sex per dose:
- Main-test: 5 males and 5 females
Pre-tests: 2 females per dose - Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: For the main study, the body weight of all animals were recorded on day 0 (shortly before the treatment), on day 7 and on day 15 (with a precision of 1 g)
- Necropsy of survivors performed: yes
- Other examinations performed: Animals were observed individually 1 h and 5 h after dosing, and once each day for 14 days thereafter. Observations included the skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic and central nervous system, and somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
All animals were subjected to gross pathology. All animals were exsanguinated under isoflurane anaesthesia. After examination of the external appearance the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs were observed. All gross pathological changes were recorded for each animal on the post mortem record sheets. The animals of preliminary study were humanely sacrificed on day 7. - Statistics:
- not applicable
- Preliminary study:
- No mortalities occured during the preliminary study
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks:
- cesium nitrate
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 1 727.6 mg/kg bw
- Based on:
- other: calculated for cesium chloride
- Mortality:
- no mortality occured
- Clinical signs:
- other: In males treated with 2000 mg/kg bw, blood around the nose (4 cases of 80 observations) was observed. This symptom (score +2) was found in two animals. It was detected between 1 and 5 hours after the treatment. However, this effect cannot be related to th
- Gross pathology:
- All animals survived until the scheduled necropsy on Day 15. Slight hydrometra was observed in one female and moderate hydrometra was found in a second female. Hydrometra was an indication for the sexual cycle of female animals and is a frequent observation in experimental rats with no toxicological meaning.
No macroscopic alterations due to the systemic toxic effects of the test item were found. - Other findings:
- none
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- An acute dermal toxicity study with cesium chloride is not available. Consequently, read-across was applied using study data from cesium nitrate. The acute dermal LD50 value of the test item cesium nitrate was greater than 2000 mg/kg bw in male and female Crl:(WI)BRrats.
Since cesium nitrate has a higher molecular weight due to the molecular weight of the counter ion the calculated value for cesium chloride is > 1728 mg/kg bw. Due to the fact that no test item related toxic effects or other changes occurred in this limit test of the structural analogous read-across substance cesium chloride was not classified as harmful category 4. - Executive summary:
An acute dermal toxicity study with cesium chloride is not available. Consequently, read-across was applied using study data from cesium nitrate.
An acute dermal toxicity study was performed with the test item cesium nitrate in Crl:(WI)BR rats, in compliance with OECD Guideline No. 402 and EU Method B.3. A limit test was carried out. A single group of male and female animals (n=5 animals/sex) was exposed to the test item at 2000 mg/kg bw by dermal route. The test item was applied in its original form and left in contact with the skin for 24 hours, followed by a 14-day observation period.
No mortality occurred after the single dermal administration of cesium nitrate at a dose of level 2000 mg/kg bw with an exposure period of 24 h. No test item related systemic toxic clinical signs were observed and no test item related effects on the animal’s body weights were established throughout the study. The general symptoms observed could not be connected to a toxic effect of the test item but may be related to the induced stress during the treatment procedure (for example due to the presence of the bandage etc.). Autopsy revealed no treatment related pathological changes. The test item did not cause dermal irritation symptoms as erythema, oedema or other signs.
In this acute dermal toxicity study with the test item cesium nitrate, the obtained acute dermal LD50 value was greater than 2000 mg/kg bw in male and female Crl:(WI)BRrats. Since cesium nitrate has a higher molecular weight due to the molecular weight of the counter ion the calculated value for cesium chloride is > 1728 mg/kg bw. Due to the fact that no test item related toxic effects or other changes occurred in this limit test of the structural analogous read-across substance cesium chloride was not classified as harmful category 4.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- An acute dermal toxicity study with cesium chloride is not available. Consequently, data from two structural analogous read-across substances, cesium nitrate and cesium iodide, were used. Both substances were tested up to the limit concentration. No test item related toxic effects or other changes were observed. Since both substances have a higher molecular weight due to the molecular weight of the counter ion the calculated value for cesium chloride is e.g. > 1728 mg/kg bw. Due to the fact that no test item related toxic effects or other changes occurred in limit tests of two structural analogous read-across substance the cesium chloride was not classified as harmful category 4.
Please refer to IUCLID section 13 for read-across justification.
Additional information
Oral:
A weight-of-evidence approach was used with different studies in mice and rats which reveal values within the same range and demonstrate the low oral toxicity of cesium chloride. An oral LD50 value of 2600 mg/kg bw in rats was used for the risk assessment.
Inhalation:
According to REACH Regulation (EC) No 1907/2006, Annex VIII, 8.5 data for a maximum of two routes of exposure need to be provided. Testing for acute toxicity via the inhalation route was not applicable as data on acute oral and acute dermal toxicity were available. Based on the results of the particle size distribution study (d10: 188 µm, d50: 344 µm, d90: 556 µm) no inhalable particles are expected. Inhalation exposure is thus expected to be negligible.
Dermal:
Key Study:
An acute dermal toxicity study with cesium chloride is not available. Consequently, read-across was applied using study data from cesium nitrate.
An acute dermal toxicity study was performed with the test item cesium nitrate in Crl:(WI)BR rats, in compliance with OECD Guideline No. 402 and EU Method B.3. A limit test was carried out. A single group of male and female animals (n=5 animals/sex) was exposed to the test item at 2000 mg/kg bw by dermal route. The test item was applied in its original form and left in contact with the skin for 24 hours, followed by a 14-day observation period.
No mortality occurred after the single dermal administration of cesium nitrate at a dose of level 2000 mg/kg bw with an exposure period of 24 h. No test item related systemic toxic clinical signs were observed and no test item related effects on the animal’s body weights were established throughout the study. The general symptoms observed could not be connected to a toxic effect of the test item but may be related to the induced stress during the treatment procedure (for example due to the presence of the bandage etc.). Autopsy revealed no treatment related pathological changes. The test item did not cause dermal irritation symptoms as erythema, oedema or other signs.
In this acute dermal toxicity study with the test item cesium nitrate, the obtained acute dermal LD50 value was greater than 2000 mg/kg bw in male and female Crl:(WI)BRrats. Since cesium nitrate has a higher molecular weight due to the molecular weight of the counter ion the calculated value for cesium chloride is > 1728 mg/kg bw. Due to the fact that no test item related toxic effects or other changes occurred in this limit test of the structural analogous read-across substance cesium chloride was not classified as harmful category 4.
Supporting Study:
An acute dermal toxicity study with cesium chloride is not available. Consequently, read-across was applied using study data from cesium iodide.
An acute dermal toxicity study was performed with the test item cesium iodide in Crl(WI)Br rats, in compliance with OECD Guideline No. 402 and EU Method B.3. A limit test was carried out. A single group of male and female animals (n=5 animals/sex) was exposed to the test item at 2000 mg/kg bw by dermal route. The test item was applied in its original form and left in contact with the skin for 24 hours, followed by a 14-day observation period.No mortality occurred after the single dermal administration of cesium iodide at a dose of level 2000 mg/kg bw with an exposure period of 24 h. No test item related systemic toxic clinical signs were observed and no test item related effects on the animal’s body weights were established throughout the study. The general symptoms observed could not be connected to a toxic effect of the test item but may be related to the induced stress during the treatment procedure (for example due to the presence of the bandage etc.). Autopsy revealed no treatment related pathological changes.
In this acute dermal toxicity study with the test item cesium iodide, the obtained acute dermal LD50 value was greater than 2000 mg/kg bw in male and female Crl(WI)Br rats.
Since cesium iodide has a higher molecular weight due to the molecular weight of the counter ion the calculated value for cesium chloride is > 1296 mg/kg bw. Due to the fact that no test item related toxic effects or other changes occurred in this limit test of the structural analogous read-across substance cesium chloride was not classified as harmful category 4.
Justification for selection of acute toxicity – oral endpoint
Data in rats
Justification for selection of acute toxicity – inhalation endpoint
According to REACH Regulation (EC) No 1907/2006, Annex VIII, 8.5 data for a maximum of two routes of exposure need to be provided. Testing for acute toxicity via the inhalation route was not applicable as data on acute oral and acute dermal toxicity were available. Based on the results of the particle size distribution study (d10: 188 µm, d50: 344 µm, d90: 556 µm) no inhalable particles are expected. Inhalation exposure is thus expected to be negligible.
Justification for selection of acute toxicity – dermal endpoint
Most reliable study with a structural analogous read-across substance
Justification for classification or non-classification
According to the results of an acute oral toxicity study with cesium chloride and acute dermal toxicity studies with two structural analogous read-across substances cesium chloride is not classified according to Regulation (EC) No 1272/2008 (CLP/GHS).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.